A detailed history of Janus Henderson Group PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 7,077,478 shares of AKRO stock, worth $201 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
7,077,478
Previous 6,876,253 2.93%
Holding current value
$201 Million
Previous $161 Million 25.87%
% of portfolio
0.11%
Previous 0.09%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.45 - $29.34 $4.32 Million - $5.9 Million
201,225 Added 2.93%
7,077,478 $203 Million
Q2 2024

Aug 14, 2024

BUY
$18.31 - $24.62 $13.8 Million - $18.6 Million
754,283 Added 12.32%
6,876,253 $161 Million
Q1 2024

May 15, 2024

BUY
$17.76 - $31.18 $32.2 Million - $56.6 Million
1,815,569 Added 42.16%
6,121,970 $155 Million
Q4 2023

Feb 14, 2024

SELL
$11.38 - $50.33 $2.05 Million - $9.08 Million
-180,325 Reduced 4.02%
4,306,401 $101 Million
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $2.54 Million - $3.22 Million
61,607 Added 1.39%
4,486,726 $227 Million
Q2 2023

Aug 14, 2023

BUY
$36.89 - $56.88 $22.6 Million - $34.9 Million
613,443 Added 16.09%
4,425,119 $207 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $50.24 $17.6 Million - $23.7 Million
471,502 Added 14.12%
3,811,676 $146 Million
Q4 2022

Feb 14, 2023

SELL
$33.44 - $54.8 $31.3 Million - $51.3 Million
-935,285 Reduced 21.88%
3,340,174 $183 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $12.3 Million - $41.1 Million
1,207,147 Added 39.34%
4,275,459 $146 Million
Q2 2022

Aug 15, 2022

SELL
$8.0 - $15.01 $2.4 Million - $4.51 Million
-300,350 Reduced 8.92%
3,068,312 $29 Million
Q1 2022

May 16, 2022

BUY
$12.97 - $22.26 $2.66 Million - $4.56 Million
205,040 Added 6.48%
3,368,662 $47.8 Million
Q4 2021

Feb 14, 2022

SELL
$19.87 - $26.24 $1.42 Million - $1.87 Million
-71,365 Reduced 2.21%
3,163,622 $66.9 Million
Q3 2021

Nov 16, 2021

SELL
$18.65 - $25.46 $4.71 Million - $6.43 Million
-252,508 Reduced 7.24%
3,234,987 $72.3 Million
Q2 2021

Aug 16, 2021

BUY
$24.81 - $32.35 $119,832 - $156,250
4,830 Added 0.14%
3,487,495 $86.5 Million
Q1 2021

May 17, 2021

SELL
$24.04 - $34.19 $258,526 - $367,679
-10,754 Reduced 0.31%
3,482,665 $101 Million
Q4 2020

Feb 16, 2021

SELL
$25.12 - $29.89 $1.06 Million - $1.26 Million
-42,036 Reduced 1.19%
3,493,419 $90.1 Million
Q3 2020

Nov 16, 2020

BUY
$30.79 - $39.92 $24.5 Million - $31.8 Million
796,937 Added 29.1%
3,535,455 $109 Million
Q2 2020

Aug 14, 2020

SELL
$19.25 - $26.76 $544,813 - $757,361
-28,302 Reduced 1.02%
2,738,518 $68.2 Million
Q1 2020

May 14, 2020

BUY
$12.8 - $27.05 $4.57 Million - $9.66 Million
357,287 Added 14.83%
2,766,820 $58.7 Million
Q4 2019

Feb 18, 2020

BUY
$17.37 - $27.27 $6.59 Million - $10.3 Million
379,505 Added 18.69%
2,409,533 $53.5 Million
Q3 2019

Nov 14, 2019

BUY
$16.89 - $29.88 $21.4 Million - $37.9 Million
1,268,875 Added 166.7%
2,030,028 $46.2 Million
Q2 2019

Jul 31, 2019

BUY
$18.08 - $19.83 $13.8 Million - $15.1 Million
761,153 New
761,153 $14.6 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.32B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.